Tumour cell proliferation, but not apoptosis, predicts survival in B-cell non-Hodgkin's lymphomas.
Tumour S-phase fraction, but not the apoptotic fraction, had prognostic value in 92 patients with B-cell non-Hodgkin's lymphoma (P < 0.0001 and P = 0.85 respectively). Multivariate analysis showed that S-phase fraction was the strongest prognostic indicator in all cases (P = 0.0003, relative risk 4.3; age: P = 0.16; grade: P = 0.81), as well as in the 63 primary biopsy cases (P = 0.0006, relative risk = 7.3; international prognostic index: P = 0.015, relative risk = 3.2; B symptoms: P = 0.017, relative risk = 3.3; bulkiness: P = 0.65; grade: P = 0.91).
Department of Biophysics, The Norwegian Radium Hospital, Montebello.
T
T
Stokke
E B
EB
Smeland
S
S
Kvaløy
H
H
Holte
D000971:Antineoplastic Combined Chemotherapy Protocols; D017209:Apoptosis; D002455:Cell Division; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D016196:S Phase; D015996:Survival Rate; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone